265 related articles for article (PubMed ID: 35847011)
1. Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents.
Vasiliu O
Front Pharmacol; 2022; 13():884155. PubMed ID: 35847011
[TBL] [Abstract][Full Text] [Related]
2. Investigational Drugs for the Treatment of Depression (Part 1): Monoaminergic, Orexinergic, GABA-Ergic, and Anti-Inflammatory Agents.
Vasiliu O
Front Pharmacol; 2022; 13():884143. PubMed ID: 35774601
[TBL] [Abstract][Full Text] [Related]
3. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
Henter ID; Park LT; Zarate CA
CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression.
Vecera CM; C Courtes A; Jones G; Soares JC; Machado-Vieira R
Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004437
[TBL] [Abstract][Full Text] [Related]
5. Glutamatergic Modulators in Depression.
Henter ID; de Sousa RT; Zarate CA
Harv Rev Psychiatry; 2018; 26(6):307-319. PubMed ID: 29465478
[TBL] [Abstract][Full Text] [Related]
6. Investigational drugs in recent clinical trials for treatment-resistant depression.
Garay RP; Zarate CA; Charpeaud T; Citrome L; Correll CU; Hameg A; Llorca PM
Expert Rev Neurother; 2017 Jun; 17(6):593-609. PubMed ID: 28092469
[TBL] [Abstract][Full Text] [Related]
7. Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.
Lener MS; Kadriu B; Zarate CA
Drugs; 2017 Mar; 77(4):381-401. PubMed ID: 28194724
[TBL] [Abstract][Full Text] [Related]
8. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
McCloud TL; Caddy C; Jochim J; Rendell JM; Diamond PR; Shuttleworth C; Brett D; Amit BH; McShane R; Hamadi L; Hawton K; Cipriani A
Cochrane Database Syst Rev; 2015 Sep; (9):CD011611. PubMed ID: 26415966
[TBL] [Abstract][Full Text] [Related]
9. [Ketamine, psilocybin, and rapid acting antidepressant: new promise for psychiatry?].
Bottemanne H; Claret A; Fossati P
Encephale; 2021 Apr; 47(2):171-178. PubMed ID: 33190819
[TBL] [Abstract][Full Text] [Related]
10. Ketamine and other glutamate receptor modulators for depression in adults.
Caddy C; Amit BH; McCloud TL; Rendell JM; Furukawa TA; McShane R; Hawton K; Cipriani A
Cochrane Database Syst Rev; 2015 Sep; (9):CD011612. PubMed ID: 26395901
[TBL] [Abstract][Full Text] [Related]
11. Esketamine for treatment‑resistant depression: A review of clinical evidence (Review).
Vasiliu O
Exp Ther Med; 2023 Mar; 25(3):111. PubMed ID: 36793329
[TBL] [Abstract][Full Text] [Related]
12. Intranasal esketamine: From origins to future implications in treatment-resistant depression.
Sanders B; Brula AQ
J Psychiatr Res; 2021 May; 137():29-35. PubMed ID: 33647726
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacology of ketamine and esketamine as rapid-acting antidepressants].
Pavlidi P; Megalokonomou A; Sofron A; Kokras N; Dalla C
Psychiatriki; 2021 Dec; 32(Supplement I):55-63. PubMed ID: 34990380
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
[TBL] [Abstract][Full Text] [Related]
15. A hypothesis of monoamine (5-HT) - Glutamate/GABA long neural circuit: Aiming for fast-onset antidepressant discovery.
Li YF
Pharmacol Ther; 2020 Apr; 208():107494. PubMed ID: 31991195
[TBL] [Abstract][Full Text] [Related]
16. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.
Meltzer-Brody S; Colquhoun H; Riesenberg R; Epperson CN; Deligiannidis KM; Rubinow DR; Li H; Sankoh AJ; Clemson C; Schacterle A; Jonas J; Kanes S
Lancet; 2018 Sep; 392(10152):1058-1070. PubMed ID: 30177236
[TBL] [Abstract][Full Text] [Related]
17. Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.
Kadriu B; Musazzi L; Henter ID; Graves M; Popoli M; Zarate CA
Int J Neuropsychopharmacol; 2019 Feb; 22(2):119-135. PubMed ID: 30445512
[TBL] [Abstract][Full Text] [Related]
18. Novel approaches for the management of depressive disorders.
Kaster MP; Moretti M; Cunha MP; Rodrigues AL
Eur J Pharmacol; 2016 Jan; 771():236-40. PubMed ID: 26703867
[TBL] [Abstract][Full Text] [Related]
19. The antidepressant effect and safety of non-intranasal esketamine: A systematic review.
Smith-Apeldoorn SY; Vischjager M; Veraart JK; Kamphuis J; Aan Het Rot M; Schoevers RA
J Psychopharmacol; 2022 May; 36(5):531-544. PubMed ID: 35546042
[TBL] [Abstract][Full Text] [Related]
20. Targeting of NMDA receptors in the treatment of major depression.
Dang YH; Ma XC; Zhang JC; Ren Q; Wu J; Gao CG; Hashimoto K
Curr Pharm Des; 2014; 20(32):5151-9. PubMed ID: 24410564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
